The product technology has been validated by major OEM's (e.g. Philips Healthcare and Siemens Medical Solutions) and dealer commitments have already been approved in several European countries. The European launch of the Trophon EPR is scheduled to start in the first half of 2009. An application for FDA regulatory approval (510k) is on target for lodgement in December 2008, with anticipated approval later in 2009 allowing marketing within North America. For more information about Nanosonics, the Trophon EPR and its platform technology (NanoNebulant(TM)) please visit the Company's websites at http://www.nanosonics.eu and http://www.trophon.com.au.
The company is of Australian origin, located in Alexandria, Sydney, with European headquarters in Hamburg, Germany. Nanosonics has been listed on the Australian Securities Exchange (NAN) and Frankfurt Stock Exchange (OQM) since 2007.
The company owns intellectual property relating to unique disinfection and sterilisation technologies, which can be suited to a variety of markets including the healthcare industry, food processing, room and space decontamination, and manufacturing.
Nanosonics is currently focused on developing infection control solutions for the global healthcare market. Initial applications are designed for the reprocessing of reusable medical instruments. The Trophon EPR is specifically designed to disinfect intracavity and surface ultrasound probes. Based on the NanoNebulant(TM) technology it surpasses the limitations of current methods by killing the most resilient micro-organisms, in a fast, safe and convenient way.
(1) Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory
Committee. Guideline for Disinfection and Sterilization in Healthcare
|SOURCE Nanosonics Europe GmbH|
Copyright©2008 PR Newswire.
All rights reserved